21世紀のFDAのがん治療用製品の承認動向
Trends in the approval of cancer therapies by the FDA in the twenty-first century p.625
doi: 10.1038/s41573-023-00723-4
Volume 22 Number 8
Review Article
がん治療薬としての抗体薬物複合体が成熟期を迎える
Antibody–drug conjugates come of age in oncology p.641
doi: 10.1038/s41573-023-00709-2
Perspective
炎症性皮膚疾患における疾患の修飾：機会と課題
Disease modification in inflammatory skin disorders: opportunities and challenges p.662
doi: 10.1038/s41573-023-00735-0
